Entera Therapeutics


Entera Therapeutics

Rosenman Innovators
Entera Therapeutics

Thirty six million people in the US suffer from Chronic Rhinosinusitis (CRS), a condition that can be debilitating and lifelong. Maximal medical treatments fail up to 50% of the time, leaving these patients with systemic drugs or surgical procedures as their only options. Entera Therapeutics is developing a novel, non-invasive drug-delivery device that empowers CRS patients to manage their disease in a non-clinical setting without significant side effects or invasive procedures.